SCHEMBL16485076

SCHEMBL16485076

c1ccc(-c2c3c(c(-c4ccccc4)c4ccccc24)-c2ccc(-c4cccc(N(c5ccccc5)c5cc(-c6cccnc6)cc(-c6cccnc6)c5)c4)c4cccc-3c24)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 1/20 0.40
FYN P06241 1/20 0.38
KMO O15229 1/20 0.34
DHPS P49366 1/20 0.34
CYP19A1 P11511 1/20 0.34
GPR84 Q9NQS5 1/20 0.33
TNF P01375 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
KCNA5 P22460 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CYP2A6 P11509 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CHEK1 O14757 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16485098 0.96 CYP11B1 (0.41) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16484426 0.95 CYP11B1 (0.39) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16484659 0.94 CYP11B1 (0.40) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16485099 0.94 CYP11B1 (0.40) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16485089 0.92 CYP11B1 (0.40) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16484096 0.92 CYP11B1 (0.39) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16484489 0.91 CYP11B1 (0.40) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL17132509 0.91 CYP11B1 (0.43) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16485078 0.91 CYP11B1 (0.40) CYP11B1CYP11B2FYNKMODHPS
SCHEMBL16484071 0.91 CYP11B1 (0.38) CYP11B1CYP11B2FYNKMODHPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2907803-B1 FLUORANTHENE DERIVATIVE, LUMINESCENT ELEMENT MATERIAL CONTAINING SAME, AND LUMINESCENT ELEMENT TORAY INDUSTRIES (JP) 2021-08-18 EP disclosed
US-9935273-B2 Fluoranthene derivative, light-emitting device material containing same, and light-emitting device TORAY INDUSTRIES, INC. (JP) 2018-04-03 US disclosed
US-9935273-B2 Fluoranthene derivative, light-emitting device material containing same, and light-emitting device TORAY INDUSTRIES, INC. (JP) 2018-04-03 US disclosed
US-20150280139-A1 FLUORANTHENE DERIVATIVE, LIGHT-EMITTING DEVICE MATERIAL CONTAINING SAME, AND LIGHT-EMITTING DEVICE TORAY INDUSTRIES, INC. (JP) 2015-10-01 US disclosed
US-20150280139-A1 FLUORANTHENE DERIVATIVE, LIGHT-EMITTING DEVICE MATERIAL CONTAINING SAME, AND LIGHT-EMITTING DEVICE TORAY INDUSTRIES, INC. (JP) 2015-10-01 US disclosed
EP-2907803-A1 FLUORANTHENE DERIVATIVE, LUMINESCENT ELEMENT MATERIAL CONTAINING SAME, AND LUMINESCENT ELEMENT Toray Industries, Inc. (JP) 2015-08-19 EP disclosed
WO-2014057874-A1 FLUORANTHENE DERIVATIVE, LUMINESCENT ELEMENT MATERIAL CONTAINING SAME, AND LUMINESCENT ELEMENT 東レ株式会社 (JP) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150280139-A1 FLUORANTHENE DERIVATIVE, LIGHT-EMITTING DEVICE MATERIAL CONTAINING SAME, AND LIGHT-EMITTING DEVICE FMNL1, AFF2, LEF1 CYP11B1 4354/4885CYP11B2 3859/4885FYN 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.